Renal agenesis medical therapy

Jump to navigation Jump to search

Renal agenesis Microchapters

Home

Patient Information

Overview

Classification

Causes

Epidemiology and Demographics

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Renal agenesis medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Renal agenesis medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Renal agenesis medical therapy

CDC on Renal agenesis medical therapy

Renal agenesis medical therapy in the news

Blogs on Renal agenesis medical therapy

Directions to Hospitals Treating Renal agenesis

Risk calculators and risk factors for Renal agenesis medical therapy

Overview

Patients with unilateral renal agenesis (URA may progress to renal insufficiency that may progress to end stage renal disease (ESRD) and therefore may require medical treatment or renal replacement therapy. The mortality rate of bilateral renal agenesis (BRA) without prenatal therapy with serial amnioinfusion, however is 100%, however, further studies are required to assess the outcome, risks and benefits of serial amnioinfusion, infancy dialysis and kidney transplantation.

Medical Therapy

Patients with unilateral renal agenesis (URA) have an increased risk for proteinuria, hypertension, and renal insufficiency that may progress to end stage renal disease (ESRD) and may require medical treatment (for example with ACE inhibitors) or renal replacement therapy (such as dialysis). (argueso) (XU) (woolf)

The mortality rate of bilateral renal agenesis (BRA) without prenatal therapy with serial amnioinfusion, however is 100%, however, further studies are required to assess the outcome, risks and benefits of this treatment. In addition, further studies are required to assess the outcome of renal replacement with dialysis in infancy and also kidney transplantation. (Huber)

References

Template:WH Template:WS